AOD9604
A 16-amino-acid fragment of human growth hormone designed to isolate fat-loss effects.
How it works
AOD9604 reproduces the C-terminal sequence (tyr-hGH 177-191) responsible for stimulating lipolysis and inhibiting lipogenesis. It does not bind the GH receptor and does not raise IGF-1.
Reported benefits
- Targeted abdominal fat reduction in early-phase human trials
- No effect on glucose tolerance or IGF-1
- Often combined with other weight-loss peptides
Dosage & administration
Research range: 250-500 mcg subcutaneously daily, often 5 days on / 2 off.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
AOD9604 for obesity, phase-2b
Trials in Obesity and Lipid Disorders · 2007
Significant fat loss vs placebo over 12 weeks at 1 mg daily.
Safety & warnings
- Generally well tolerated in phase-2 data
- Possible injection-site irritation
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
5 mg
5AD
Box of 10 · $303
Single vial · $606
10 mg
10AD
Box of 10 · $555
Single vial · $1,110
Related guides
Tirzepatide
A first-in-class dual GIP and GLP-1 receptor agonist that has reset the standard for pharmacologic weight loss.
Semaglutide
The long-acting GLP-1 analogue that opened the modern era of injectable weight management.
Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing unprecedented weight loss in phase-2 data.